PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
2138364-1	1990	We evaluated the in vitro anticoagulant action of dermatan sulfate (DS) (aPTT, antiXa, anti-thrombin) and its effect on human platelet aggregation and beta TG/PF4 release induced by threshold doses of aggregating agents, compared with standard heparin (SH).	Dermatan Sulfate	50-66	platelet factor 4	Homo sapiens	159-162	
3123254-3	1987	The PF4 kinetics, in the presence of heparan and dermatan sulphate, reflected the different affinities that PF4 has for these GAGs.	Dermatan Sulfate	49-66	platelet factor 4	Homo sapiens	4-7	
2763268-6	1989	PF4 affinity for GAGs is as follows: heparin greater than heparan sulphate much greater than dermatan sulphate.	Dermatan Sulfate	93-110	platelet factor 4	Homo sapiens	0-3	
3123254-3	1987	The PF4 kinetics, in the presence of heparan and dermatan sulphate, reflected the different affinities that PF4 has for these GAGs.	Dermatan Sulfate	49-66	platelet factor 4	Homo sapiens	108-111	
3123254-9	1987	Although part of the protamine will displace PF4 from the binding sites of the dermatan sulphate molecule, the remaining part of protamine could probably be bound to this GAG without losing its activity so that, upon subsequent heparin injection, it is immediately neutralized, rendering it unavailable for further PF4 harvesting.	Dermatan Sulfate	79-96	platelet factor 4	Homo sapiens	45-48	
8656041-3	1996	We found that binding of iodine 125-labeled PF4 to HEL cells was inhibited by heparin, heparan sulfate, and dermatan sulfate and to a smaller extent by chondroitin sulfate.	Dermatan Sulfate	108-124	platelet factor 4	Homo sapiens	44-47